5-Amino-1MQ: What It Is, How It Works, and What the Research Shows

5-Amino-1MQ is a small molecule, not a true peptide, that blocks NNMT, an enzyme tied to NAD+ use and fat-cell metabolism. Early animal and cell studies suggest possible effects on fat storage and energy balance, but human evidence is limited. It is not FDA-approved for any human use. [1][2][8]

What is 5-Amino-1MQ?

5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is often called a “peptide” online, but chemically it is a small molecule in the NNMT inhibitor drug class. NNMT stands for nicotinamide N-methyltransferase, an enzyme that helps convert nicotinamide into 1-methylnicotinamide, also called 1-MNA. [1][2][3]

It is discussed in longevity and body-composition settings because NNMT is active in visceral adipose tissue, the deeper belly fat linked with metabolic risk. Some animal and lab studies suggest NNMT inhibition may affect NAD+ levels, SIRT1 activity, fat-cell size, insulin sensitivity, and mitochondrial energy use. These findings are early and do not prove the same results in people. Side effects and long-term risks are not well defined. [1][2][3]

Is 5-Amino-1MQ actually a peptide?

No. A true peptide is made of amino acids linked in a chain. 5-Amino-1MQ is a small molecule. The “amino” in its name refers to a chemical group, not a peptide chain. This matters because peptides and small molecules can differ in stability, absorption, testing, and safety concerns. [1]

How it differs from GLP-1 medications like semaglutide and tirzepatide

Semaglutide, sold under brand names including Ozempic and Wegovy and also available as compounded semaglutide through licensed 503A pharmacies when legally appropriate, is a GLP-1 receptor agonist. Tirzepatide, sold under brand names including Mounjaro and Zepbound and also available as compounded tirzepatide through licensed 503A pharmacies when legally appropriate, is a GIP and GLP-1 receptor agonist. These medicines have FDA-approved uses and large human trials; 5-Amino-1MQ does not. GLP-1 medicines also have known side effects, including nausea, vomiting, diarrhea, constipation, gallbladder problems, pancreatitis warnings, and boxed warnings about thyroid C-cell tumors in rodents. [4][5][6][7]

How does 5-Amino-1MQ work?

5-Amino-1MQ is studied as an NNMT blocker, with NAD+ as one key pathway. NNMT activity is linked with how cells handle nicotinamide, NAD+, and methyl groups. NAD+ is a coenzyme that helps cells make energy, while SIRT1 is a NAD+-dependent protein involved in stress response and metabolic signaling. [1][2][3][10]

The NNMT enzyme and fat storage

Research in fat tissue suggests NNMT can influence energy use and fat-cell behavior. In mouse models, lowering or blocking NNMT activity was linked with smaller fat cells and improved metabolic markers. These are preclinical findings, so they should not be read as proof of human weight-loss benefit. Unknown side effects, drug interactions, and long-term safety risks remain important. [1][2]

How NAD+ and SIRT1 fit in

NNMT uses nicotinamide and can affect NAD+ balance. NAD+ supports mitochondrial function and ATP production, and SIRT1 uses NAD+ to help regulate metabolic pathways. This is why some clinics discuss 5-Amino-1MQ with NAD+ support. That combination has not been proven in large human trials, and people with cancer, liver disease, kidney disease, pregnancy, or complex medication lists should discuss risks with a clinician. [3][10][11]

Effects on fat cells and metabolism

Preclinical studies suggest NNMT inhibition may increase energy expenditure and reduce fat accumulation in certain models. These are not guaranteed effects in humans. Possible risks are not well defined, and interactions with diabetes medicines, stimulants, cancer therapies, thyroid medicines, or NAD+-related supplements have not been well studied. [1][2][10][11]

What does the research say about 5-Amino-1MQ?

5-Amino-1MQ has stronger preclinical evidence than human evidence, and large human outcome trials are not available. The best-known work includes cell and animal studies of NNMT inhibition in fat tissue and cancer biology. These studies help explain possible mechanisms, but they cannot confirm safety, best candidates, or real-world outcomes in people. [1][2][11]

Preclinical evidence for weight and metabolic effects

In a 2018 preclinical study, Kannt and colleagues studied small-molecule NNMT inhibition, including 5-amino-1-methylquinolinium, in cellular and mouse models of metabolic disease. The study reported changes in metabolic markers in animals, but it was not a randomized human weight-loss trial, and individual human results cannot be predicted from it. Side effects in humans were not established by this animal work. [1]

A separate 2014 mouse study found that lowering NNMT activity in fat tissue was linked with protection against diet-induced metabolic changes. This supports NNMT as a research target, not as a proven treatment for people. Human safety, dosing, monitoring, and long-term risk remain unanswered. [2]

Cancer and other exploratory research

NNMT is also being studied in cancer because tumor metabolism can involve NAD+ and methylation pathways. This does not mean 5-Amino-1MQ treats, cures, or prevents cancer. It means NNMT is an investigational target. People with cancer or a cancer history should only discuss NNMT-related products with an oncology clinician because benefits, harms, and interactions are uncertain. [11][12]

What we do not yet know in humans

• Whether 5-Amino-1MQ leads to meaningful weight, waist, or metabolic changes in adults. [1][2]
• Which patients, if any, are most likely to benefit. [1]
• Long-term safety, including liver, kidney, heart, hormone, fertility, and cancer-related risks. [8][11]
• How it interacts with GLP-1 medicines, diabetes medicines, NAD+ products, stimulants, thyroid medicines, or cancer therapies. [4][5][10][11]
• Which route, formulation, or schedule has the best safety profile in people. [8][9]

How long does it take to see results from 5-Amino-1MQ?

There is no proven human timeline for 5-Amino-1MQ results because no FDA-reviewed treatment schedule exists. Some clinics may discuss changes over weeks, but that is not the same as evidence from large controlled trials. Animal studies can show metabolic changes over short study periods, yet those timelines do not translate directly to people. [1][2][8]

If a person is using any investigational or compounded product, results can be affected by sleep, food intake, activity, other medicines, health conditions, and lab monitoring. Side effects or lack of benefit should be reviewed with the prescribing clinician rather than managed with self-directed dose changes. [9]

What are the potential side effects of 5-Amino-1MQ?

The side-effect profile of 5-Amino-1MQ is not well established because published human safety data are limited. Online reports may mention nausea, headache, fatigue, appetite changes, or injection-site irritation, but these reports are not the same as FDA-reviewed clinical trial data. The lack of a known risk is not proof of safety. [8][9]

Reported effects and tolerability

Because 5-Amino-1MQ is not FDA-approved for any human use, there is no FDA-reviewed adverse-event table for patients. In contrast, FDA-approved GLP-1 medicines have labels that list common and serious risks. For example, semaglutide and tirzepatide labels include gastrointestinal side effects and warnings about pancreatitis, gallbladder disease, kidney injury from dehydration, and thyroid C-cell tumors in rodents. [4][5]

Drug interactions to discuss with a clinician

Because NNMT connects with NAD+ metabolism, methylation, fat-cell function, and cancer biology, unknown interactions matter. People should discuss diabetes medicines, blood pressure medicines, stimulants, thyroid medicines, NAD+ products, niacin or nicotinamide supplements, chemotherapy, and hormone therapy with a clinician before considering any NNMT-related compound. [3][10][11]

Who should avoid 5-Amino-1MQ?

Because 5-Amino-1MQ is not FDA-approved and lacks robust human safety data, some groups should be especially cautious. This includes people who are pregnant, trying to become pregnant, breastfeeding, under 18, or living with serious liver, kidney, heart, endocrine, or cancer-related conditions. [8][9][11]

• People with a current or past cancer diagnosis should ask an oncology clinician before considering NNMT-related products. [11][12]
• People using diabetes medicines should ask about low blood sugar risk if appetite, weight, or food intake changes. [4][5]
• People using NAD+ injections, nicotinamide riboside, niacin, or similar supplements should ask whether overlapping NAD+ pathway effects matter. [3][10]
• People with many medications should have a clinician review for interactions. [9]
• Anyone considering a compounded product needs a valid prescription and an evaluation by a licensed clinician. [9]

5-Amino-1MQ vs. GLP-1 medications: how do they compare?

5-Amino-1MQ and GLP-1 medicines are different categories, and only the GLP-1 options have FDA-approved labels for specific uses. Semaglutide is a GLP-1 receptor agonist with FDA-approved products for type 2 diabetes and chronic weight management, depending on the brand and indication. Tirzepatide is a GIP and GLP-1 receptor agonist with FDA-approved products for type 2 diabetes and chronic weight management, depending on the brand and indication. Both have labeled side effects and contraindications; 5-Amino-1MQ does not have an FDA-reviewed label. [4][5][6][7][8]

How is 5-Amino-1MQ taken and dosed?

There is no FDA-approved 5-Amino-1MQ dose, route, or schedule, and no FDA label exists for human use. Clinics may describe oral or injectable compounded forms, but dosing should not be copied from online forums, research suppliers, or wellness blogs. Any compounded medication requires a valid prescription and a clinician who can review health history, labs, risks, and goals. [8][9]

For comparison, FDA-approved weight-management medications do have labeled dosing schedules. The FDA-approved Wegovy label lists 0.25 mg semaglutide once weekly as the initial escalation dose and 2.4 mg once weekly as the recommended maintenance dose. The FDA-approved Zepbound label lists 2.5 mg tirzepatide once weekly as the starting dose and 5 mg, 10 mg, or 15 mg once weekly as recommended maintenance doses. These label numbers are not instructions for any individual person; they show how FDA-approved medications differ from 5-Amino-1MQ, which has no approved human dosing label. [4][5]

A safe discussion should cover why the product is being considered, what evidence supports that goal, what side effects are known or unknown, what monitoring is reasonable, and when to stop. No one should use research-only powder meant for lab use as a substitute for a prescribed medication. [9]

How can you access 5-Amino-1MQ safely?

5-Amino-1MQ should be approached as an investigational, non-FDA-approved compound, and a valid prescription is required for any compounded medication. The safer path, if a clinician thinks it is appropriate, is through a licensed provider and a licensed 503A compounding pharmacy. A 503A pharmacy can compound certain patient-specific medications under federal and state rules when there is a valid prescription. [9]

Research-only powders vs. compounded prescriptions

Research-only powders sold online are not intended for human consumption. They may not meet prescription standards for sterility, potency, storage, or contaminant testing. A compounded prescription is different: it is prepared for an individual patient after a licensed clinician decides the product is appropriate and documents the prescription. [9]

Getting a clinical evaluation through Chia

Chia is one option for a clinician-reviewed telehealth evaluation for compounded GLP-1 medications and select longevity peptides, when appropriate and legally available. For 5-Amino-1MQ, a clinician should review FDA status, the limited human evidence, medication interactions, and FDA-approved alternatives before any prescription is considered. [4][5][8][9]

Frequently asked questions

Keep reading

Weight Loss

How to Get Weight Loss Medication: Eligibility, Options, and Costs

GLP-1 Weight Loss

How to Get Weight-Loss Injections Online: A Step-by-Step Guide

Peptides

Peptide Injections: What They Are, How They Work, and What to Expect